CNBC's Angelica Peebles joins 'Money Movers' to discuss the battle between Eli Lilly and Novo Nordisk over GLP-1 obesity pills.
Breakdown
- Eli Lilly and Novo Nordisk will soon conduct a head-to-head trial of their GLP-1 obesity pills. 33s
- Lilly's pill recently showed less weight loss than hoped, shifting investor attention to Novo Nordisk. 22s
- Analysts predict oral GLP-1 drugs could capture 20% of the obesity drug market by 2030. 1m 23s
- Injectable drugs are expected to remain more effective than pills for significant weight loss. 1m 51s
- Novo Nordisk is seeking FDA approval to add cardiovascular benefits to its oral drug label. 2m 42s